cagrilintide novo Nordisk flags promise in hunt for next obesity drug Data on Novo Nordisk experimental

Data on Novo Nordisk experimental weight loss drug show mostly mild side effects Reuters Novo Nordisk announces positive results for CagriSema in type 2 diabetes PMLiVE Trial Scorecard: REDEFINE 1 and 2 Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement # Novo Nordisk A S: CagriSema demonstrated 23% weight loss in an open label head to head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

SKU: 98710639947 · From creatorsinfotech.com